The total overall mutation rate of SLC30s was 43.77% in cervical carcinoma patients, with individual rates for SLC30A1, SLC30A2, SLC30A3, SLC30A4, SLC30A5, SLC30A6, SLC30A7, SLC30A8, SLC30A9, SLC30A10 of 6%, 3%, 3%, 5%, 7%, 10%, 7%, 5%, 11%, 6% (Figure 4C). Here, SLC30A2 is linked to cervical carcinoma.